WS Investor
16 Nov 2026, 16:18
Johnson & Johnson to Acquire Ollin Biosciences for $2.2 Billion, Adding Phase 3 Eye-Disease Drug
Johnson & Johnson (NYSE: JNJ) agreed to acquire clinical-stage biotech Ollin Biosciences for $2.2 billion upfront, expanding its ophthalmology pipeline with a late-stage treatment for serious retinal diseases.
The transaction also includes potential regulatory and commercial milestone payments of up to approximately $1.125 billion.
Ollin’s lead asset, OLN324, is a Phase 3 investigational bispecific antibody targeting both VEGF and Ang2, two important pathways involved in retinal vascular disease. The therapy is being developed for wet age-related macular degeneration and diabetic macular edema, conditions that collectively affect more than 40 million people worldwide.
Johnson & Johnson said OLN324’s high Ang2 potency and smaller antibody format could improve control of retinal fluid and potentially allow longer intervals between treatments.
The company is also entering into a separate development funding agreement with Blackstone Life Sciences. Blackstone will provide $750 million over multiple years to fully fund Phase 3 development of OLN324. In return, Blackstone will be eligible for certain regulatory and sales milestone payments as well as single-digit royalties.
The acquisition is expected to close before the end of 2026, subject to regulatory approvals and customary closing conditions.
Strategically, the deal strengthens Johnson & Johnson’s ophthalmology portfolio and adds a late-stage asset with potential exposure to two large retinal-disease markets. It also limits near-term development funding requirements through the separate Blackstone financing arrangement.
Johnson & Johnson (NYSE: JNJ) agreed to acquire clinical-stage biotech Ollin Biosciences for $2.2 billion upfront, expanding its ophthalmology pipeline with a late-stage treatment for serious retinal diseases.
The transaction also includes potential regulatory and commercial milestone payments of up to approximately $1.125 billion.
Ollin’s lead asset, OLN324, is a Phase 3 investigational bispecific antibody targeting both VEGF and Ang2, two important pathways involved in retinal vascular disease. The therapy is being developed for wet age-related macular degeneration and diabetic macular edema, conditions that collectively affect more than 40 million people worldwide.
Johnson & Johnson said OLN324’s high Ang2 potency and smaller antibody format could improve control of retinal fluid and potentially allow longer intervals between treatments.
The company is also entering into a separate development funding agreement with Blackstone Life Sciences. Blackstone will provide $750 million over multiple years to fully fund Phase 3 development of OLN324. In return, Blackstone will be eligible for certain regulatory and sales milestone payments as well as single-digit royalties.
The acquisition is expected to close before the end of 2026, subject to regulatory approvals and customary closing conditions.
Strategically, the deal strengthens Johnson & Johnson’s ophthalmology portfolio and adds a late-stage asset with potential exposure to two large retinal-disease markets. It also limits near-term development funding requirements through the separate Blackstone financing arrangement.